Ploughing through a crowded PD-(L)1 market, BeiGene loads up on promising lung cancer data

BeiGene’s entry to the PD-1 market — as the fourth domestic drugmaker to score approval in China, lagging months behind multinational players — might have been unremarkable. But the follow-up act is where it plans to shine. Three months after posting positive top-line progression-free survival results for their pivotal Chinese

Read the full article here

Related Articles